Clinical Trial Update: A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease [Phase 2]

View source ↗

Summary

Phase 2 results for the drug KAN-101 in people with celiac disease have been posted, detailing its efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Celiac Disease

Drugs mentioned

• KAN-101

Snippet

Sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | Conditions: Celiac Disease, Coeliac Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-12-18